Rhythm Pharmaceutical (RYTM) IPO Opens Up 37%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- Marvell Technology shares rise on analyst support
Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
October 4, 2017 9:08 PM EDTBOSTON, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for treatment of rare genetic deficiencies that result in life-threatening metabolic disorders, today announced the pricing of its initial public offering of 7,050,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts. All of the shares are being offered by Rhythm. In addition, Rhythm has granted the underwriters a 30-day option to purchase up to an additional 1,057,500 shares of common stock at the initial public offering price. The shares are scheduled... More



